Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

21.03.2018 | short review | Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018

Indolent lymphoma at ASH (American Society of Hematology) 2017: maintenance revisited

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2018
Autor:
MD Thomas Nösslinger

Summary

At the last ASH (American Society of Hematology) meeting a new prognostic tool for follicular lymphoma (FL), based on the patient cohort of the PRIMA trial (PRIMA-PI, Primary Rituximab and Maintenance-Prognostic Index), was presented. The 10-year update of the PRIMA trial confirms the continuous advantage in progression-free survival of rituximab maintenance after R‑CHOP induction without new safety signals. Similarly rituximab maintenance is beneficial in FL after first-line chemoimmunotherapy with rituximab–bendamustine. Currently checkpoint inhibitors are under investigation in different treatment lines of FL. The earlier ibrutinib is administered in relapsed mantle cell lymphoma, the more effective the long-term efficacy is. New, more selective inhibitors of the Bruton’s tyrosine kinase (BTK) may be an option for patients in whom ibrutinib may be contraindicated.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018 Zur Ausgabe